Navigation Links
Actinium Pharmaceuticals Clinical Results Featured at a United Nations Forum
Date:7/9/2013

NEW YORK, July 9, 2013 /PRNewswire/ -- Actinium Pharmaceuticals Inc. (OTCQB: ATNM), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics for treatment of advanced cancers, announced that the Actinium Pharmaceuticals' clinical programs and platform technology were presented in Vienna, Austria, at a technical meeting at the International Atomic Energy Agency (IAEA). The presentation was delivered by Dr. David Scheinberg, Interim Director of the Sloan-Kettering Institute, research division of the Memorial Sloan-Kettering Cancer Center.

"There is increasing interest in the uses of alpha particle therapy around the world," said Dr. Scheinberg. "We now see scientists, clinicians, isotope manufacturers, government agencies and commercial companies collaborating to enable therapeutic advances of these agents against cancer." 

Dr. Scheinberg's presentation focused on Actinium Pharmaceuticals' drug candidates Actimab-A and Bismab for acute myeloid leukemia as well as applications of alpha immunotherapy in treatment of solid cancers. The IAEA meeting at the United Nations headquarters in Vienna, Austria, was a closed workshop entitled "Alpha Emitting Radionuclides and Radiopharmaceuticals for Therapy".

About Actimab - A
Actimab-A is a drug candidate construct made using Actinium Pharmaceuticals' proprietary patented technology for arming monoclonal antibodies with alpha emitters actinium-225 and bismuth-213.  Antibodies are used as high precision delivery systems that bring powerful alpha emitters into or immediately next to targeted cancer cells. Actimab-A consists of the Lintuzumab monoclonal antibody and actinium-225.

Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed. The technology was first developed by Dr. David Scheinberg at Memorial Sloan-Kettering Cancer Center.

About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. is a New York, NY based biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 radiopharmaceuticals in association with monoclonal antibodies.

For more information:
Visit our web site www.actiniumpharmaceuticals.com or

Contact:
Segio Traversa, CEO
Actinium Pharmaceuticals Inc.
E-mail: straversa@actiniumpharmaceuticals.com

Media:
Dennis S. Dobson Jr.
Tel: (203) 258-0159
E-mail: dsdobson@optonline.com  
www.dobsonmediagroup.com

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance.  No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE Actinium Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actinium Pharmaceuticals, Inc. Receives $3.5m from Exercise of Warrants
2. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
3. Actinium Pharmaceuticals, Inc. Receives Notice of Patent Allowance for a Key Application
4. Cactus Ventures, Inc. Changes Name to Actinium Pharmaceuticals, Inc.
5. Actinium Pharmaceuticals, Inc. To Present at the 15th Annual BIO CEO Investor Conference
6. Actinium Pharmaceuticals to Present at EMIT Targeted Radiotherapy Conference
7. University of Pennsylvania joins Actinium Pharmaceuticals Multicenter Actimab-A Trial
8. Additional Clinical Data from Two Trials on Actinium Pharmaceuticals Iomab-B to be Presented at American Society of Hematology (ASH) Annual Meeting
9. Actinium Pharmaceuticals Sponsors Webinar on Clinical Use of Alpha Immunotherapy
10. Actinium Pharmaceuticals Announces New Round of Financing
11. Gerri Henwood Joins Actinium Pharmaceuticals as Chief Development Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2017)... June 3, 2017  Eli Lilly and Company ... results from the Phase 3 MONARCH 2 study ... 6 inhibitor, in combination with fulvestrant, significantly improved ... alone in women with hormone-receptor-positive (HR+), human epidermal ... who have relapsed or progressed after endocrine therapy ...
(Date:5/30/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will present at ... on Tuesday, June 13, 2017, in Rancho Palos ... and chief executive officer, is scheduled to present at 3:20 ... be accessed at http://ir.hill-rom.com/events.cfm . A recorded replay will ... through September 13, 2017. ...
(Date:5/26/2017)... Calif. , May 25, 2017  In response ... States , Direct Relief is working with Pfizer ... Naloxone available at no cost to community health centers, ... nonprofit providers nationwide. "Pfizer has a ... to medicines and ensuring patient safety through educational activities," ...
Breaking Medicine Technology:
(Date:6/26/2017)... ... June 26, 2017 , ... ... is revolutionizing the way women look and feel about themselves and their sexual ... female sexual dysfunction and urinary leakage head on with a ground breaking medical ...
(Date:6/26/2017)... Antonio, TX (PRWEB) , ... June 26, 2017 ... ... physicians, their coding staff, and consumers are seeing lots of red these days. ... receive contain inaccurate charges that result from medical coding errors(1). Some studies point ...
(Date:6/26/2017)... Fitchburg, WI (PRWEB) , ... June 26, 2017 , ... ... implant consultations from Dr. Angela Cotey, with or without a referral. Dr. Cotey is ... the benefits of this preferred tooth replacement option. , Patients with missing teeth in ...
(Date:6/25/2017)... Viejo, CA (PRWEB) , ... June 24, 2017 , ... Create a feel-good lyric music ... presets above footage and sound in the timeline and write in the lyrics to any ... before flying back out. Each line of the text can be added modularly for optimal ...
(Date:6/25/2017)... ... 25, 2017 , ... An increase in wetter weather in the Northern California ... with that; a humdinger of an allergy season. A relief from drought conditions is ... misery-causing grass and weed pollen. , “Our patients have been reporting the typical ...
Breaking Medicine News(10 mins):